Skip to main content
PMC home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1992 Jan;105(1):45–50. doi: 10.1111/j.1476-5381.1992.tb14208.x

Characterization of vascular neuropeptide Y receptors.

L Grundemar 1, S E Jonas 1, N Mörner 1, E D Högestätt 1, C Wahlestedt 1, R Håkanson 1
PMCID: PMC1908598  PMID: 1317737

Abstract

1. In the present study we compared neuropeptide Y (NPY) and NPY-related analogues for their ability to activate or bind to vascular NPY receptors in four experimental set-ups. Previous results have suggested the existence of different receptor subtypes, Y1 receptors requiring full-length NPY (1-36) or [Pro34]-NPY, and Y2 receptors recognizing also N-terminally truncated forms of NPY but not [Pro34]-NPY. 2. NPY 1-36 and [Pro34]-NPY dose-dependently increased arterial pressure in the anaesthetized rat with a similar magnitude and potency. NPY 2-36 was much less potent than NPY 1-36. NPY 4-36 and NPY 11-36 were inactive even at a dose as high as 10 nmol kg-1. 3. NPY 1-36, [Pro34]-NPY, NPY 2-36 and NPY 5-36 concentration-dependently increased the coronary resistance in the Langendorff preparation of the rat. NPY 1-36 and [Pro34]-NPY were equipotent, while NPY 2-36 and NPY 5-36 were about 7 and 20 times less potent. At 0.3 microM, NPY 11-36, NPY 20-36 and NPY 22-36 induced a slight contraction while NPY 23-36 was inactive. 4. NPY 1-36, [Pro34]-NPY, NPY 2-36, NPY 4-36, NPY 5-36 and NPY 11-36 evoked concentration-dependent contractions in the isolated inferior caval vein of the rat and guinea-pig. [Pro34]-NPY was more potent than NPY 1-36. NPY 2-36 was equipotent with NPY 1-36, while NPY 4-36, NPY 5-36 and NPY 11-36 were approximately 30 times less potent.(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
46

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allen J. M., Bircham P. M., Edwards A. V., Tatemoto K., Bloom S. R. Neuropeptide Y (NPY) reduces myocardial perfusion and inhibits the force of contraction of the isolated perfused rabbit heart. Regul Pept. 1983 Jul;6(3):247–253. doi: 10.1016/0167-0115(83)90143-x. [DOI] [PubMed] [Google Scholar]
  2. Boublik J. H., Scott N. A., Brown M. R., Rivier J. E. Synthesis and hypertensive activity of neuropeptide Y fragments and analogues with modified N- or C-termini or D-substitutions. J Med Chem. 1989 Mar;32(3):597–601. doi: 10.1021/jm00123a014. [DOI] [PubMed] [Google Scholar]
  3. Boublik J., Scott N., Taulane J., Goodman M., Brown M., Rivier J. Neuropeptide Y and neuropeptide Y18-36. Structural and biological characterization. Int J Pept Protein Res. 1989 Jan;33(1):11–15. doi: 10.1111/j.1399-3011.1989.tb00677.x. [DOI] [PubMed] [Google Scholar]
  4. Chamley-Campbell J., Campbell G. R., Ross R. The smooth muscle cell in culture. Physiol Rev. 1979 Jan;59(1):1–61. doi: 10.1152/physrev.1979.59.1.1. [DOI] [PubMed] [Google Scholar]
  5. Dumont Y., Fournier A., St-Pierre S., Schwartz T. W., Quirion R. Differential distribution of neuropeptide Y1 and Y2 receptors in the rat brain. Eur J Pharmacol. 1990 Dec 4;191(3):501–503. doi: 10.1016/0014-2999(90)94189-5. [DOI] [PubMed] [Google Scholar]
  6. Ekblad E., Edvinsson L., Wahlestedt C., Uddman R., Håkanson R., Sundler F. Neuropeptide Y co-exists and co-operates with noradrenaline in perivascular nerve fibers. Regul Pept. 1984 Apr;8(3):225–235. doi: 10.1016/0167-0115(84)90064-8. [DOI] [PubMed] [Google Scholar]
  7. Grundemar L., Håkanson R. Effects of various neuropeptide Y/peptide YY fragments on electrically-evoked contractions of the rat vas deferens. Br J Pharmacol. 1990 May;100(1):190–192. doi: 10.1111/j.1476-5381.1990.tb12075.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Grundemar L., Wahlestedt C., Shen G. H., Zukowska-Grojec Z., Håkanson R. Biphasic blood pressure response to neuropeptide Y in anesthetized rats. Eur J Pharmacol. 1990 Apr 10;179(1-2):83–87. doi: 10.1016/0014-2999(90)90404-t. [DOI] [PubMed] [Google Scholar]
  9. Håkanson R., Wahlestedt C., Ekblad E., Edvinsson L., Sundler F. Neuropeptide Y: coexistence with noradrenaline. Functional implications. Prog Brain Res. 1986;68:279–287. doi: 10.1016/s0079-6123(08)60244-7. [DOI] [PubMed] [Google Scholar]
  10. Högestätt E. D., Andersson K. E., Edvinsson L. Mechanical properties of rat cerebral arteries as studied by a sensitive device for recording of mechanical activity in isolated small blood vessels. Acta Physiol Scand. 1983 Jan;117(1):49–61. doi: 10.1111/j.1748-1716.1983.tb07178.x. [DOI] [PubMed] [Google Scholar]
  11. Krstenansky J. L., Owen T. J., Payne M. H., Shatzer S. A., Buck S. H. C-terminal modifications of neuropeptide Y and its analogs leading to selectivity for the mouse brain receptor over the porcine spleen receptor. Neuropeptides. 1990 Nov;17(3):117–120. doi: 10.1016/0143-4179(90)90073-8. [DOI] [PubMed] [Google Scholar]
  12. Lundberg J. M., Stjarne L. Neuropeptide Y (NPY) depresses the secretion of 3H-noradrenaline and the contractile response evoked by field stimulation, in rat vas deferens. Acta Physiol Scand. 1984 Mar;120(3):477–479. doi: 10.1111/j.1748-1716.1984.tb07410.x. [DOI] [PubMed] [Google Scholar]
  13. Lundberg J. M., Tatemoto K., Terenius L., Hellström P. M., Mutt V., Hökfelt T., Hamberger B. Localization of peptide YY (PYY) in gastrointestinal endocrine cells and effects on intestinal blood flow and motility. Proc Natl Acad Sci U S A. 1982 Jul;79(14):4471–4475. doi: 10.1073/pnas.79.14.4471. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Lundberg J. M., Terenius L., Hökfelt T., Martling C. R., Tatemoto K., Mutt V., Polak J., Bloom S., Goldstein M. Neuropeptide Y (NPY)-like immunoreactivity in peripheral noradrenergic neurons and effects of NPY on sympathetic function. Acta Physiol Scand. 1982 Dec;116(4):477–480. doi: 10.1111/j.1748-1716.1982.tb07171.x. [DOI] [PubMed] [Google Scholar]
  15. Macho P., Pérez R., Huidobro-Toro J. P., Domenech R. J. Neuropeptide Y (NPY): a coronary vasoconstrictor and potentiator of catecholamine-induced coronary constriction. Eur J Pharmacol. 1989 Aug 11;167(1):67–74. doi: 10.1016/0014-2999(89)90748-6. [DOI] [PubMed] [Google Scholar]
  16. Maturi M. F., Greene R., Speir E., Burrus C., Dorsey L. M., Markle D. R., Maxwell M., Schmidt W., Goldstein S. R., Patterson R. E. Neuropeptide-Y. A peptide found in human coronary arteries constricts primarily small coronary arteries to produce myocardial ischemia in dogs. J Clin Invest. 1989 Apr;83(4):1217–1224. doi: 10.1172/JCI114004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Meyer-Lehnert H., Schrier R. W. Potential mechanism of cyclosporine A-induced vascular smooth muscle contraction. Hypertension. 1989 Apr;13(4):352–360. doi: 10.1161/01.hyp.13.4.352. [DOI] [PubMed] [Google Scholar]
  18. Rioux F., Bachelard H., Martel J. C., St-Pierre S. The vasoconstrictor effect of neuropeptide Y and related peptides in the guinea pig isolated heart. Peptides. 1986 Jan-Feb;7(1):27–31. doi: 10.1016/0196-9781(86)90056-2. [DOI] [PubMed] [Google Scholar]
  19. Schwartz T. W., Fuhlendorff J., Kjems L. L., Kristensen M. S., Vervelde M., O'Hare M., Krstenansky J. L., Bjørnholm B. Signal epitopes in the three-dimensional structure of neuropeptide Y. Interaction with Y1, Y2, and pancreatic polypeptide receptors. Ann N Y Acad Sci. 1990;611:35–47. doi: 10.1111/j.1749-6632.1990.tb48920.x. [DOI] [PubMed] [Google Scholar]
  20. Sheikh S. P., Håkanson R., Schwartz T. W. Y1 and Y2 receptors for neuropeptide Y. FEBS Lett. 1989 Mar 13;245(1-2):209–214. doi: 10.1016/0014-5793(89)80223-6. [DOI] [PubMed] [Google Scholar]
  21. Uddman R., Ekblad E., Edvinsson L., Håkanson R., Sundler F. Neuropeptide Y-like immunoreactivity in perivascular nerve fibres of the guinea-pig. Regul Pept. 1985 Mar;10(2-3):243–257. doi: 10.1016/0167-0115(85)90019-9. [DOI] [PubMed] [Google Scholar]
  22. Vleeming W., van der Wouw P. A., van Rooij H. H., Wemer J., Porsius A. J. In vitro method for measurement of cardiac performance and responses to inotropic drugs after experimentally induced myocardial infarction in the rat. J Pharmacol Methods. 1989 Apr;21(2):95–102. doi: 10.1016/0160-5402(89)90027-2. [DOI] [PubMed] [Google Scholar]
  23. Wahlestedt C., Grundemar L., Håkanson R., Heilig M., Shen G. H., Zukowska-Grojec Z., Reis D. J. Neuropeptide Y receptor subtypes, Y1 and Y2. Ann N Y Acad Sci. 1990;611:7–26. doi: 10.1111/j.1749-6632.1990.tb48918.x. [DOI] [PubMed] [Google Scholar]
  24. Wahlestedt C., Håkanson R., Vaz C. A., Zukowska-Grojec Z. Norepinephrine and neuropeptide Y: vasoconstrictor cooperation in vivo and in vitro. Am J Physiol. 1990 Mar;258(3 Pt 2):R736–R742. doi: 10.1152/ajpregu.1990.258.3.R736. [DOI] [PubMed] [Google Scholar]
  25. Walker M. W., Miller R. J. 125I-neuropeptide Y and 125I-peptide YY bind to multiple receptor sites in rat brain. Mol Pharmacol. 1988 Dec;34(6):779–792. [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES